Lipocine controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile2 entries
2021
Lipocine and Clarus enter global settlement agreement
Settlement
Lipocine and Clarus Therapeutics entered into a global settlement agreement to resolve outstanding claims in their intellectual-property litigation and an interference proceeding between the companies.
Stated objective. Resolve all outstanding claims in the ongoing intellectual-property litigation and the ongoing interference proceeding between the companies.
Source excerpt
Entered into a global settlement agreement with Clarus Therapeutics Inc. ("Clarus") to resolve all outstanding claims in the on-going intellectual property litigation between Lipocine and Clarus, as well as the on-going interference proceeding between the two companies
2020
Judge postpones Lipocine–Clarus patent trial
Ruling
Judge William C. Bryson of the U.S. District Court of Delaware postponed the jury trial scheduled for February 8, 2021, in Lipocine's patent litigation against Clarus Therapeutics because of the ongoing effects of the COVID-19 pandemic. Lipocine alleges that Clarus's JATENZO product infringes its U.S. patents; the trial is to be rescheduled when jury trials resume in the district.
Source excerpt
In the pending suit against Clarus Therapeutics, Inc. ("Clarus") Lipocine is alleging that Clarus's JATENZO® product infringes Lipocine's U.S. patents: 9,034,858; 9,205,057; 9,480,690; and 9,757,390.
today announced that Judge William C. Bryson of the United States District Court of Delaware has postponed the February 8, 2021 jury trial scheduled to hear arguments in the patent litigation case of Lipocine Inc. vs. Clarus Therapeutics Inc. due to the ongoing effects of the COVID-19 pandemic.